Interactive demonstration · no sign-up
Is your next study necessary?
Explore three real evidence sets compiled from PubMed. Include or exclude studies, add a hypothetical next study, and see how Evidentia’s model measures support, uncertainty and expected information gain.
Step 1
Start with a question
A scientific claim is broken into its core elements, so that every study can be judged against the same question.
“Vitamin D supplementation reduces the risk of acute respiratory tract infections.”
- Population
- Children and adults
- Intervention
- Vitamin D supplementation
- Outcome
- Acute respiratory tract infection
Step 2
Listen to the studies
84 PubMed records were screened; 40 did not directly test the claim and are not counted. Each remaining study supports or contradicts the claim. Untick a study to see how the picture changes.
- SupportsEffects of vitamin D supplementation on acute respiratory tract infections in 6-8-year-old children: a randomized clinical trial.(PubMed, opens in a new tab)
Clerico et al. (2025). Eur J Nutr. PMID 40310565
“The vitamin D-supplemented children had 17% fewer sick days due to ARTI (risk ratio (RR), 0.83; 95% CI, 0.76-0.90; P < 0.001) compared with placebo.”
Screening note: RCT in children found vitamin D supplementation significantly reduced days with ARTI versus placebo, consistent with the claim.
- ContradictsA randomized trial of vitamin D supplementation to prevent seasonal influenza and enterovirus infection in children.(PubMed, opens in a new tab)
Huang et al. (2022). J Microbiol Immunol Infect. PMID 35283046
“The vitamin D group showed a relative risk reduction of 84% against influenza compared to the placebo group but did not reach statistical significance.”
Screening note: RCT in children found no statistically significant reduction in influenza (p=0.055) and no effect on enterovirus infection, so it does not show a meaningful protective effect.
- ContradictsWeekly Vitamin D Supplementation to Prevent Acute Respiratory Infections in Young Children at Different Latitudes: A Randomized Controlled Trial.(PubMed, opens in a new tab)
Reyes et al. (2024). J Pediatr. PMID 39181322
“However, no group differences were observed in number of ARI (P = .85), ARI hospitalizations (P = .20), LL-37/cathelicidin change (P = .30), or adverse events (P = .41).”
Screening note: This RCT directly tested vitamin D supplementation in preschoolers and found no reduction in the number of acute respiratory infections.
- ContradictsEffect of Monthly High-Dose Vitamin D Supplementation on Acute Respiratory Infections in Older Adults: A Randomized Controlled Trial.(PubMed, opens in a new tab)
Camargo et al. (2020). Clin Infect Dis. PMID 31420647
“The hazard ratio for vitamin D compared with placebo was 1.01 (95% CI, 0.94, 1.07).”
Screening note: Large RCT found no reduction in acute respiratory infection with monthly high-dose vitamin D versus placebo, including in those with low baseline 25(OH)D.
- SupportsEffect of Vitamin D supplementation to reduce respiratory infections in children and adolescents in Vietnam: A randomized controlled trial.(PubMed, opens in a new tab)
Loeb et al. (2019). Influenza Other Respir Viruses. PMID 30328294
“When considering all respiratory viruses, including influenza, the effect of vitamin D in reducing infection was significant, HR: 0.81, 95% CI: 0.66-0.99.”
Screening note: The RCT found vitamin D reduced non-influenza and overall respiratory viral infections, though not influenza alone (the primary outcome). The overall direction is mostly supportive.
- ContradictsEffects of Maternal Vitamin D Supplementation During Pregnancy and Lactation on Infant Acute Respiratory Infections: Follow-up of a Randomized Trial in Bangladesh.(PubMed, opens in a new tab)
Morris et al. (2021). J Pediatric Infect Dis Soc. PMID 34213544
“Incidence of microbiologically confirmed ARI in the high-dose prenatal plus postpartum vitamin D (1.21 episodes per 6 person-months; N = 235) and placebo groups (1.07 episodes per 6 person-months; N = 234) was not significantly different (hazard ratio of 1.12 [95% confidence intervals: 0.90-1.40]).”
Screening note: The randomized trial directly tested vitamin D supplementation for ARI and found no reduction in infant ARI risk.
- ContradictsA randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections.(PubMed, opens in a new tab)
Li-Ng et al. (2009). Epidemiol Infect. PMID 19296870
“There was no difference in the incidence of URIs between the vitamin D and placebo groups (48 URIs vs. 50 URIs, respectively, P=0.57).”
Screening note: RCT of vitamin D3 versus placebo found no difference in incidence, duration, or severity of upper respiratory infections.
- SupportsHigh-Dose Monthly Vitamin D for Prevention of Acute Respiratory Infection in Older Long-Term Care Residents: A Randomized Clinical Trial.(PubMed, opens in a new tab)
Ginde et al. (2017). J Am Geriatr Soc. PMID 27861708
“The high-dose group had 0.67 ARIs per person-year and the standard-dose group had 1.11 (incidence rate ratio (IRR) = 0.60, 95% confidence interval (CI) = 0.38-0.94, P = .02).”
Screening note: RCT directly tests vitamin D for ARI prevention and finds significantly fewer ARIs with high-dose supplementation, although falls were more frequent.
Step 3
See the bigger picture
Supporting and contradicting studies update a uniform prior into a posterior for the study-support rate, with its probability above one half and a 95% credible interval.
Contradiction-dominant pattern
Beta(1,1) → Beta(14,32)
13 support · 31 contradict · N = 44
p · study-support rate
P(p > 0.5)
0.3%
95% credible interval
18.2%–44.3%
Posterior mean
30.4%
Bayes factor BF₁₀
0.00332
Posterior odds ÷ prior odds for p > 0.5
The curve describes plausible values of the study-support rate p. The dashed line is the uniform prior and the shaded band the 95% equal-tailed interval. It is not the probability that the claim is true, and each informative study counts once regardless of size or quality.
Step 4
Is the next study necessary?
Expected information gain estimates how much one more eligible, informative study would change what we know, averaged over whether it supports or contradicts.
Expected information gain · one more informative study
0.0107 nats
Relative to the maximum for one study, ln(2) − ½ ≈ 0.1931 nats, reached with no prior evidence.
REIG is descriptive. It is not a measure of certainty or a rule to conduct research; a research recommendation also requires source review, substantive importance, feasibility and ethics.
How this demonstration was built
Every study is a real PubMed record, linked by its PMID. Records were retrieved on 2026-11-18 with the search below and ordered by PubMed relevance.
SRI screened each abstract once with an automated classifier as supporting, contradicting or not informative, and quoted one verbatim sentence from the abstract. Classifications were not reviewed by Evidentia or by peer review, and this is not a systematic review. Use the PubMed links to check any study.
Statistics use Evidentia’s published model: p ∼ Beta(1,1) updated to Beta(1 + y, 1 + n); P(p > 0.5); a 95% equal-tailed credible interval; EIG = m·K₁ + (1 − m)·K₀ with m = α/(α + β) and K the KL divergence after one hypothetical outcome; REIG = EIG ÷ (ln 2 − ½).
PubMed search used
(vitamin D[tiab] OR cholecalciferol[tiab]) AND supplement*[tiab] AND (respiratory tract infection*[tiab] OR acute respiratory infection*[tiab] OR upper respiratory infection*[tiab] OR influenza[tiab] OR common cold[tiab] OR pneumonia[tiab]) AND randomized controlled trial[pt] NOT (review[pt] OR meta-analysis[pt])Run this on your own scientific claim.
In Evidentia you define the claim, add your studies and receive a traceable report.